Orchid Island Capital Inc. (ORC): More likely the dividends will be cut ne...

More likely the dividends will be cut next

JMCK6193 · 2023-09-26T16:45:54.1930000Z

More likely the dividends will be cut next month. I sure hope not.

Play Episode

6min

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

Technology Minerals CEO on black mass and Leinster milestones

Technology Minerals CEO Alex Stanbury talked with Proactive's Stephen Gunnion about a milestone week for the company, highlighting significant progress in both its recycling operations and exploration asset portfolio. Stanbury discussed the first shipment of black mass from its Recyclus facility to Europe, under an agreement with Glencore. He explained that black mass—a hazardous material containing lithium, cobalt, and nickel—requires complex approvals for cross-border movement. “It’s been a lot of work in the making to get this black mass moved off-site,” Stanbury said, noting this completes a critical part of the company’s business model. He also commented on the importance of the Glencore partnership, stating that “for Glencore to have the faith to work with us…is really important.” This collaboration ensures a consistent offtake of all Recyclus production. Stanbury also confirmed Recyclus is working with Ocado, managing end-of-life batteries from their robotic systems. The company uses its proprietary LiBoxes to safely store and transport used lithium-ion batteries, providing safety and ESG compliance. “We’ve done thousands of batteries for them now and there’s an ongoing maintenance programme,” he added. Finally, Technology Minerals has completed the sale of its Leinster lithium project in Ireland, aligning with its strategy of incubating early-stage assets and moving them up the value curve. The company is now focused on its Spanish project, which benefits from EU interest in critical materials and battery manufacturing. It expects further licenses to be granted soon and aims to seek JV partners to bring the project toward feasibility and production. For more updates, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #TechnologyMinerals #Recyclus #Glencore #BlackMass #BatteryRecycling #CriticalMetals #Ocado #LithiumRecycling #LiBoxes #ESG #SustainableMining #E

Proactive - Interviews for investors

Lithium ION Energy secures joint venture with SureFQ to advance Urgakh Naran Lithium project

Lithium ION Energy Limited CEO Ali Haji joined Steve Darling from Proactive to announce a binding Joint Venture Agreement with SureFQ for the advancement of the Urgakh Naran lithium project in Mongolia. Under the agreement, ION will retain a 20% free carried interest through to commercial production, ensuring long-term participation in the project's success without additional financial commitments. SureFQ, a firm specializing in sustainable energy solutions and lithium resource development, will leverage its industry expertise and advanced extraction technologies to accelerate the project’s progress. As a strategic investor, SureFQ focuses on developing high-potential assets that support the global energy transition. Haji told Proactive SureFQ will provide $5.5 million in cash considerations to ION over 4.5 years. The company has committed to $8 million in development expenditures for Urgakh Naran over four years. ION Energy will maintain a 2.5% Net Smelter Return (NSR) royalty in perpetuity, ensuring a steady revenue stream from future production. Haji emphasized that ION Energy is a proven Direct Lithium Extraction (DLE) operator, focused on deploying modular extraction capacity to optimize efficiency. This partnership positions Urgakh Naran as a key lithium asset in Mongolia, furthering ION’s role in the global battery metals supply chain. #proactiveinvestors #lithiumionenergylimited #tsxv #ion #urgakhnaran #mongolia #lithium #IonEnergy #AliHaji #UrgakhNaran #SureFQ #MongoliaMining #LithiumExtraction #DLETechnology #BatteryMetals #EVSupplyChain #CriticalMinerals #MiningInvestment #ProactiveInvestors #JuniorMining

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Followers	29
Posts	5600
Boards Moderated	0
Alias Born	09/07/2012

Volume:	2,552,065
Day Range:	7.36 - 7.5803
Bid:
Ask:
Last Trade Time:	3:07:29 PM EDT
Total Trades:	12,083

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ORC Detailed Quote

Recent ORC News

More ORC News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ORC News

Go Ad-Free